Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merck & Co Inc MRK

Healthcare
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for... see more

Recent & Breaking News (NYSE:MRK)

Merck KGaA: Form 8 (DD) - AZ Electronic Materials S.A.

Marketwired April 23, 2014

FDA Approves Merck's RAGWITEK(TM) (Short Ragweed Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Short Ragweed Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Adults

Business Wire April 17, 2014

Merck Serono's President & CEO Belén Garijo has Been Appointed to Board of Directors of L'Oréal

PR Newswire April 17, 2014

FDA Approves Merck's GRASTEK® (Timothy Grass Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Grass Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Children and Adults

Business Wire April 14, 2014

Merck's Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection

Business Wire April 11, 2014

Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Naïve Patients with Genotype 1 Infection

Business Wire April 10, 2014

Early Findings Exploring the Relationship of PD-L1 Expression and Clinical Outcomes with MK-3475, Merck's Investigational Anti-PD-1 Immunotherapy, Presented at AACR Annual Meeting 2014

Business Wire April 6, 2014

Merck, Ferring Pharmaceuticals and the World Health Organization Working Together to Prevent Excessive Bleeding in Women after Childbirth

Business Wire April 4, 2014

Merck Announces Appointment of Robert M. Davis as Chief Financial Officer; Succeeds Peter N. Kellogg, Who Has Served in the Role Since 2007

Business Wire March 27, 2014

Merck to Present New Data for Investigational Hepatitis C Treatments MK-5172 and MK-8742 at EASL Annual Meeting/The International Liver Congress(TM) 2014

Business Wire March 24, 2014

Endocyte (ECYT) Doubles on Successful Vintafolide Trial

Equities.com March 21, 2014

Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT® (vintafolide) and Companion Imaging Agents FOLCEPRI® (etarfolatide) and NEOCEPRI® (Intravenous (IV) folic acid) in Patients with Platinum-Resistant ...

Business Wire March 21, 2014

Merck to Hold First-Quarter 2014 Sales and Earnings Conference Call on April 29

Business Wire March 20, 2014

Promising Biotechs Target New Ways to Kill Bad Bugs: Venture Capitalist Dennis Purcell

Equities.com March 19, 2014

King: How the Oncology Drug Development Machine Builds Biotech Wealth

Equities.com March 17, 2014

FDA Approves Merck's NOXAFIL® (posaconazole) Injection (18 mg/mL) for Intravenous Use

Business Wire March 14, 2014

Merck's Investigational Hepatitis C Treatment Regimen MK-5172/MK-8742 Shows Robust Anti-HCV Activity in HIV/HCV Co-Infected Patients with HCV Genotype 1 Infection

Business Wire March 5, 2014

Merck's Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Naïve Adults

Business Wire March 5, 2014

New 96-Week ACTG Study Results Presented at CROI 2014; First Large Study Comparing ISENTRESS® (raltegravir) Regimen to Two Protease Inhibitor Regimens in Previously Untreated Adults with HIV-1

Business Wire March 5, 2014

Arrowhead Research Hits 52-Week High on Strong Coverage

Equities.com March 5, 2014